| Literature DB >> 31382599 |
Andréa A M Shimojo1,2, Ana Rita V Fernandes3, Nuno R E Ferreira4, Elena Sanchez-Lopez3,5,6, Maria H A Santana7, Eliana B Souto8,9.
Abstract
Resveratrol (RSV) is a natural antioxidant commonly found in grapes, berries, and nuts that has shown promising results in the treatment of a variety of degenerative and age-related diseases. Despite the proven beneficial results on reduction of reactive oxidant species (ROS) and on inflammatory process, RSV shows various limitations including low long-term stability, aqueous solubility, and bioavailability, restricting its applications in the medical-pharmaceutical area. To overcome these limitations, it has been applied in pharmaceutical formulations as nanostructured lipid carriers (NLC). Thus, the present study focuses on the optimization of the production process of NLC. NLC was produced by high shear homogenization (HSH) and ultrasound method (US) using Compritol® ATO C888 as solid lipid and Miglyol 812® as liquid lipid. In order to obtain an optimized formulation, we used a 22 full factorial design with triplicate of central point investigating the effects of the production process parameters; shear intensity and homogenization time, on the mean particle size (PS) and polydispersity index (PDI). Instability index, encapsulation efficiency, and production yield were also evaluated. As the PS and PDI values obtained with 6 min of shear at 19,000 rpm and 10 min of shear and 24,000 rpm were similar, the instability index (<0.1) was also used to select the optimal parameters. Based on the results of the experimental design and instability index, it was concluded that the shear rate of 19,000 rpm and the shear time of 6 min are the optimal parameters for RSV-loaded NLC production. Factorial design contributed therefore to optimize the variables of the NLC production process from a small number of experiments.Entities:
Keywords: factorial design; high shear homogenization; nanostructured lipid carriers (NLC); resveratrol; ultrasound method
Year: 2019 PMID: 31382599 PMCID: PMC6719996 DOI: 10.3390/antiox8080272
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Preparation of resveratrol-loaded nanostructured lipid carriers (NLC). Factorial design, providing the lower (−1), upper (+1), and (0) central point level values for each variable.
| Factor | Coded Levels | ||
|---|---|---|---|
| −1 | 0 | +1 | |
| Shear intensity (rpm) | 13,000 | 19,000 | 24,000 |
| Shear time (minutos) | 2 | 6 | 10 |
A 22 full factorial experimental design layout. The formulation codes of NLC with resveratrol are named as NLC-RSV(number of the experiment) and the one without resveratrol as NLC(number of the experiment).
| Formulation Code | Coded Factor Level | |
|---|---|---|
| Factor 1 | Factor 2 | |
| NLC1 or NLC-RSV1 | −1 | −1 |
| NLC2 or NLC-RSV2 | +1 | −1 |
| NLC3 or NLC-RSV3 | −1 | +1 |
| NLC4 or NLC-RSV4 | +1 | +1 |
| NLC5 or NLC-RSV5 | 0 | 0 |
| NLC6 or NLC-RSV6 | 0 | 0 |
| NLC7 or NLC-RSV7 | 0 | 0 |
Influence of shear intensity and homogenization time on the production of NLC.
| Shear Time (minutes) | Shear Intensity (rpm) | PS ± SD (nm) | PDI ± SD | Zeta ± SD (mV) | Entrapment Efficiency (%) | Production Yield (%) | Instability Index * | |
|---|---|---|---|---|---|---|---|---|
| NLC1 | 2 | 13,000 | 263.6 ± 3.9 | 0.465 ± 0.020 | −12.97 ± 0.50 | - | 97 ± 2 | 0.022 |
| NLC2 | 10 | 13,000 | 190.3 ± 1.8 | 0.429 ± 0.025 | −10.02 ± 0.24 | - | 78 ± 4 | 0.044 |
| NLC3 | 2 | 24,000 | 111.6 ± 1.1 | 0.236 ± 0.001 | −13.93 ± 0.47 | - | 73.5 ± 0.6 | 0.040 |
| NLC4 | 10 | 24,000 | 178.3 ± 1.6 | 0.478 ± 0.022 | −12.03 ± 0.51 | - | 66 ± 1 | 0.034 |
| NLC5 | 6 | 19,000 | 109.1 ± 0.7 | 0.265 ± 0.008 | −10.03 ± 0.23 | - | 71 ± 3 | 0.043 |
| NLC6 | 6 | 19,000 | 103.4 ± 1.5 | 0.279 ± 0.036 | −11.00 ± 0.46 | - | 68 ± 13 | 0.03 |
| NLC7 | 6 | 19,000 | 106.4 ± 0.1 | 0.271 ± 0.006 | −12.83 ± 0.35 | - | 65.8 ± 0.9 | 0.032 |
| NLC-RSV1 | 2 | 13,000 | 164.3 ± 3.2 | 0.619 ± 0.010 | −13.23 ± 0.21 | 94.6 ± 0.4 | 76.1 ± 0.9 | 0.073 |
| NLC-RSV2 | 10 | 13,000 | 187.7 ± 0.9 | 0.464 ± 0.003 | −8.43 ± 0.15 | 94.4 ± 0.1 | 78 ± 2 | 0.493 |
| NLC-RSV3 | 2 | 24,000 | 153.1 ± 1.0 | 0.366 ± 0.005 | −12.07 ± 0.40 | 96.3 ± 0.1 | 72 ± 3 | 0.041 |
| NLC-RSV4 | 10 | 24,000 | 142.9 ± 2.5 | 0.353 ± 0.016 | −11.67 ± 0.70 | 94.2 ± 0.1 | 69 ± 1 | 0.244 |
| NLC-RSV5 | 6 | 19,000 | 125.3 ± 0.5 | 0.357 ± 0.009 | −12.87 ± 0.38 | 92.9 ± 0.4 | 67.9 ± 0.6 | 0.024 |
| NLC-RSV6 | 6 | 19,000 | 139.4 ± 0.7 | 0.339 ± 0.006 | −12.90 ± 0.27 | 93.15 ± 0.04 | 62 ± 4 | 0.025 |
| NLC-RSV7 | 6 | 19,000 | 146.6 ± 3.2 | 0.444 ± 0.061 | −13.00 ± 0.53 | 92.0 ± 0.3 | 63 ± 11 | 0.011 |
SD = standard deviation; PDI = polydispersity index. * Instability index measured at t = 200 s.
Figure 1Micrographs obtained by TEM of (a) NLC4 and (b) NLC-RSV4. Scale bar = 500 nm.
Figure 2Pareto charts of the standardized effects for the placebo obtained for (a) particle size (Z-average) and (b) polydispersity index (PDI).
Figure 3Surface response charts of experimental design of the placebo obtained for (a) particle size (Z-average) and (b) polydispersity index (PDI).
Figure 4Pareto charts of the standardized effects for RSV-loaded NLC obtained for (a) particle size (Z-average) and (b) polydispersity index (PDI).
Figure 5Surface response charts of experimental design of RSV-loaded NLC obtained for (a) particle size (Z-average) and (b) polydispersity index (PDI).